Literature DB >> 7841311

Heterogeneity of plasma tissue factor pathway inhibitor.

G J Broze1, G W Lange, K L Duffin, L MacPhail.   

Abstract

Much of tissue factor pathway inhibitor (TFPI) in plasma is bound to lipoproteins. The major form of TFPI associated with low density lipoproteins (LDL) is 34 kDa, whereas that associated with high density lipoproteins (HDL) is 41 kDa and appears in part to represent a mixed disulphide complex between TFPI and apolipoprotein AII. The native and recombinant TFPI produced by mammalian cells in tissue culture and the TFPI released by heparin in vivo, however, are 34 kDa. Western blotting with antibodies raised against specific TFPI peptides and cation exchange chromatography under denaturing conditions of partially purified plasma TFPI suggest that only a fraction of TFPI circulating in plasma is in the form of the full length molecule, the remainder consisting of variably carboxyl-terminal truncated forms. Electrospray mass spectrometry of the isolated 34 kDa form of plasma TFPI, which predominantly circulates bound to LDL, confirms that it lacks a substantial portion of the carboxyl-terminus including at least a portion of the third Kunitz-type domain.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7841311

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  24 in total

1.  TFPIβ is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes.

Authors:  Thomas J Girard; Elodee Tuley; George J Broze
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

2.  The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition.

Authors:  Matthew Ndonwi; Elodee A Tuley; George J Broze
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

3.  Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology.

Authors:  T J Girard; K Grunz; N M Lasky; J P Malone; G J Broze
Journal:  J Thromb Haemost       Date:  2018-10-22       Impact factor: 5.824

4.  The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va.

Authors:  M Ndonwi; T J Girard; G J Broze
Journal:  J Thromb Haemost       Date:  2012-09       Impact factor: 5.824

5.  Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception.

Authors:  Pansakorn Tanratana; Paul Ellery; Pamela Westmark; Alan E Mast; John P Sheehan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-02       Impact factor: 8.311

6.  Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor.

Authors:  A E Mast; D A Higuchi; Z F Huang; I Warshawsky; A L Schwartz; G J Broze
Journal:  Biochem J       Date:  1997-10-15       Impact factor: 3.857

7.  Active tissue factor pathway inhibitor is expressed on the surface of coated platelets.

Authors:  Susan A Maroney; Sandra L Haberichter; Paul Friese; Maureen L Collins; Josephine P Ferrel; George L Dale; Alan E Mast
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

8.  The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo.

Authors:  I Warshawsky; G Bu; A Mast; J E Saffitz; G J Broze; A L Schwartz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.

Authors:  Connie Duckers; Paolo Simioni; Luca Spiezia; Claudia Radu; Sabrina Gavasso; Jan Rosing; Elisabetta Castoldi
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

Review 10.  Biology of tissue factor pathway inhibitor.

Authors:  Jeremy P Wood; Paul E R Ellery; Susan A Maroney; Alan E Mast
Journal:  Blood       Date:  2014-03-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.